Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ibuprofen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchIbuprofenIbuprofen (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study

Abu Esba et al., Infectious Diseases and Therapy, doi:10.1007/s40121-020-00363-w
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Mortality -170% Improvement Relative Risk Mortality (b) 37% Oxygen therapy -45% Hospitalization -18% Severe case -85% Ibuprofen  Abu Esba et al.  EARLY TREATMENT Is early treatment with ibuprofen beneficial for COVID-19? Prospective study of 397 patients in Saudi Arabia (Apr - Jun 2020) Higher mortality (p=0.35) and severe cases (p=0.42), not sig. c19early.org Abu Esba et al., Infectious Diseases a.., Nov 2020 Favors ibuprofen Favors control
Prospective study of 503 COVID-19 cases in Saudi Arabia, 40 using ibuprofen during infection, and 357 not using NSAIDs, showing no significant differences in outcomes. Results are subject to confounding by indication.
This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
risk of death, 169.5% higher, RR 2.70, p = 0.35, treatment 1 of 40 (2.5%), control 11 of 357 (3.1%), adjusted per study, multivariable.
risk of death, 36.8% lower, HR 0.63, p = 0.68, treatment 40, control 357, Cox proportional hazards.
risk of oxygen therapy, 44.8% higher, RR 1.45, p = 0.64, treatment 40, control 357, adjusted per study, multivariable.
risk of hospitalization, 18.2% higher, RR 1.18, p = 0.64, treatment 40, control 357, adjusted per study, multivariable.
risk of severe case, 84.8% higher, RR 1.85, p = 0.42, treatment 40, control 357, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abu Esba et al., 2 Nov 2020, prospective, Saudi Arabia, peer-reviewed, 6 authors, study period 12 April, 2020 - 1 June, 2020. Contact: abuesbala@ngha.med.sa.
This PaperIbuprofenAll
Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study
Laila Carolina Abu Esba, Rahaf Ali Alqahtani, Abin Thomas, Nour Shamas, Lolowa Alswaidan, Gahdah Mardawi
Infectious Diseases and Therapy, doi:10.1007/s40121-020-00363-w
Introduction: Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes. Methods: We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVID-19 were included. Information on NSAID use was collected through a telephone questionnaire, and patients were followed up for COVID-19 infection outcomes, including death, admission, severity, time to clinical improvement, oxygen requirement and length of stay. Results: Acute use of ibuprofen was not associated with a greater risk of mortality relative to non-use (adjusted hazard ratio [HR] 0.632 [95% CI 0.073-5.441; P = 0.6758]). Chronic NSAID use was also not associated with a greater risk of mortality (adjusted HR 0.492 [95% CI 0.178-1.362; P = 0.1721]). Acute ibuprofen use was not associated with a higher risk of admission compared to non-NSAID users (adjusted odds ratio OR 1.271; 95% CI 0.548-2.953). NSAID users did not have a significantly longer time to clinical improvement or length of stay. Conclusion: Acute or chronic use of ibuprofen and other NSAIDs was not associated with worse COVID-19 disease outcomes.
References
Agency, EMA gives advice on the use of nonsteroidal anti-inflammatories for COVID-19
Amici, Coro, Ciucci, Chiappa, Castilletti et al., Indomethacin has a potent antiviral activity against SARS coronavirus, Antiviral Therapy
Castro, Ross, Mcbride, Perlis, Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records, doi:10.1101/2020.04.11.20061994
Chandler, Global ibuprofen shortage hits UK supermarkets-with shelves left empty
Clinicaltrials, Gov, Efficacy of addition of naproxen in the treatment of critically ill patients hospitalized for COVID-19 infection
Curhan, Bullock, Hankinson, Willett, Speizer et al., Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women, Pharmacoepidemiol Drug Saf
Drug, Usf, FDA advises patients on use of nonsteroidal anti-inflammatory drugs (NSAIDs) for COVID-19
Fang, Karakiulakis, Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med
Gov, Uk, COVID-19
Khan, Benthin, Zeno, Albertson, Boyd et al., A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome, Crit Care
Kuba, Imai, Rao, Gao, Guo et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat Med
Lejal, Tarus, Bouguyon, Chenavas, Bertho et al., Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus, Antimicrob Agents Chemother
Liu, Yang, Zhang, Huang, Wang et al., Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci China Life Sci
Micallef, Soeiro, Ap, French Society of Pharmacology, Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology and COVID-19 infection, Therapies, doi:10.1016/j.therap.2020.05.003
News, Concerned about taking ibuprofen for coronavirus symptoms? Here's What Experts Say
News, Coronavirus and ibuprofen: separating fact from fiction
Paulose-Ram, Hirsch, Dillon, Gu, Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among US adults, Pharmacoepidemiol Drug Saf
Qiao, Wang, Chen, Zhang, Liu et al., Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats, Cardiology
Safidahaj, Re, Response to the emerging novel coronavirus outbreak
Smart, Fawkes, Goggin, A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality, Inflammopharmacol, doi:10.1007/s10787-020-00745-z
Times, Managing and Treating Fever: A Guide to Nonprescription Antipyretics
Today, Fact check: does using ibuprofen when you have coronavirus make symptoms worse?
Wan, Shang, Graham, Baric, Li, Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus, J Virol, doi:10.1128/JVI.00127-20
Wh, R&D Blueprint and COVID-19
Willsher, Anti-inflammatories may aggravate Covid-19
Yang, Gu, Zhao, Wang, Cao et al., Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury, Sci Rep
Zheng, Zhang, Jiao, Shang, Cui, Naproxen exhibits broad anti-influenza virus activity in mice impeding viral nucleoprotein nuclear export, Cell Rep
{ 'indexed': {'date-parts': [[2022, 8, 6]], 'date-time': '2022-08-06T13:52:16Z', 'timestamp': 1659793936156}, 'reference-count': 28, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2020, 11, 2]], 'date-time': '2020-11-02T00:00:00Z', 'timestamp': 1604275200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2020, 11, 2]], 'date-time': '2020-11-02T00:00:00Z', 'timestamp': 1604275200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 3]]}, 'DOI': '10.1007/s40121-020-00363-w', 'type': 'journal-article', 'created': {'date-parts': [[2020, 11, 2]], 'date-time': '2020-11-02T04:18:16Z', 'timestamp': 1604290696000}, 'page': '253-268', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 31, 'title': 'Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A ' 'Prospective Cohort Study', 'prefix': '10.1007', 'volume': '10', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-2459-1485', 'authenticated-orcid': False, 'given': 'Laila Carolina', 'family': 'Abu Esba', 'sequence': 'first', 'affiliation': []}, {'given': 'Rahaf Ali', 'family': 'Alqahtani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abin', 'family': 'Thomas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nour', 'family': 'Shamas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lolowa', 'family': 'Alswaidan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gahdah', 'family': 'Mardawi', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 11, 2]]}, 'reference': [ { 'key': '363_CR1', 'unstructured': 'Times P. Managing and Treating Fever: A Guide to Nonprescription ' 'Antipyretics 2018. ' 'https://www.pharmacytimes.com/publications/issue/2018/February2018/managing-and-treating-fever-a-guide-to-nonprescription-antipyretics. ' 'Accessed 19 March 2020.'}, { 'key': '363_CR2', 'unstructured': 'Chandler M. Global ibuprofen shortage hits UK supermarkets—with shelves ' 'left empty. 2019. ' 'https://www.mirror.co.uk/news/uk-news/global-ibuprofen-shortage-hits-uk-20465178. ' 'Accessed 1 April 2020.'}, { 'key': '363_CR3', 'unstructured': 'News B. Coronavirus and ibuprofen: separating fact from fiction. 2020. ' 'https://www.bbc.com/news/51929628. Accessed 1 April 2020.'}, { 'key': '363_CR4', 'unstructured': 'Today U. Fact check: does using ibuprofen when you have coronavirus make ' 'symptoms worse? 2020. ' 'https://www.usatoday.com/story/news/factcheck/2020/03/18/fact-check-coronavirus-and-ibuprofen-do-nsaids-make-coronavirus-worse/2865866001/. ' 'Accessed 1 April 2020.'}, { 'key': '363_CR5', 'unstructured': 'News N. Concerned about taking ibuprofen for coronavirus symptoms? ' "Here's What Experts Say. 2020. " 'https://www.npr.org/sections/health-shots/2020/03/18/818026613/advice-from-france-to-avoid-ibuprofen-for-covid-19-leaves-experts-baffled. ' 'Accessed 1 April 2020.'}, { 'key': '363_CR6', 'unstructured': 'Willsher K. Anti-inflammatories may aggravate Covid-19, France advises. ' '2020. ' 'https://www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. ' 'Accessed 1 April 2020.'}, { 'issue': '4', 'key': '363_CR7', 'doi-asserted-by': 'publisher', 'first-page': 'e21', 'DOI': '10.1016/S2213-2600(20)30116-8', 'volume': '8', 'author': 'L Fang', 'year': '2020', 'unstructured': 'Fang L, Karakiulakis G, Roth M. Are patients with hypertension and ' 'diabetes mellitus at increased risk for COVID-19 infection? Lancet ' 'Respir Med. 2020;8(4):e21.', 'journal-title': 'Lancet Respir Med'}, { 'key': '363_CR8', 'unstructured': 'Agency EM. EMA gives advice on the use of non-steroidal ' 'anti-inflammatories for COVID-19. 2020. ' 'https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19. ' 'Accessed 3 May 2020.'}, { 'key': '363_CR9', 'doi-asserted-by': 'publisher', 'unstructured': 'Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common ' 'pharmacotherapies associated with reduced COVID-19 morbidity using ' 'electronic health records. medRxiv. 2020. ' 'https://doi.org/10.1101/2020.04.11.20061994', 'DOI': '10.1101/2020.04.11.20061994'}, { 'key': '363_CR10', 'unstructured': 'DRUG USF. FDA advises patients on use of non-steroidal anti-inflammatory ' 'drugs (NSAIDs) for COVID-19. 2020. ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19. ' 'Accessed 3 May 2020.'}, { 'key': '363_CR11', 'unstructured': 'GOV.UK. Commission on Human Medicines advice on ibuprofen and ' 'coronavirus (COVID-19). 2020. ' 'https://www.gov.uk/government/news/commission-on-human-medicines-advice-on-ibuprofen-and-coronavirus-covid-19. ' 'Accessed 3 May 2020.'}, { 'key': '363_CR12', 'doi-asserted-by': 'publisher', 'unstructured': 'Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the ' 'novel coronavirus from Wuhan: an analysis based on decade-long ' 'structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–20. ' 'PMID: 31996437; PMCID: PMC7081895. https://doi.org/10.1128/JVI.00127-20', 'DOI': '10.1128/JVI.00127-20'}, { 'issue': '2', 'key': '363_CR13', 'doi-asserted-by': 'publisher', 'first-page': '97', 'DOI': '10.1159/000375362', 'volume': '131', 'author': 'W Qiao', 'year': '2015', 'unstructured': 'Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen ' 'attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. ' 'Cardiology. 2015;131(2):97–106.', 'journal-title': 'Cardiology'}, { 'issue': '4', 'key': '363_CR14', 'doi-asserted-by': 'publisher', 'first-page': '257', 'DOI': '10.1002/pds.983', 'volume': '14', 'author': 'R Paulose-Ram', 'year': '2005', 'unstructured': 'Paulose-Ram R, Hirsch R, Dillon C, Gu Q. Frequent monthly use of ' 'selected non-prescription and prescription non-narcotic analgesics among ' 'US adults. Pharmacoepidemiol Drug Saf. 2005;14(4):257–66.', 'journal-title': 'Pharmacoepidemiol Drug Saf.'}, { 'issue': '8', 'key': '363_CR15', 'doi-asserted-by': 'publisher', 'first-page': '687', 'DOI': '10.1002/pds.732', 'volume': '11', 'author': 'GC Curhan', 'year': '2002', 'unstructured': 'Curhan GC, Bullock AJ, Hankinson SE, Willett WC, Speizer FE, Stampfer ' 'MJ. Frequency of use of acetaminophen, nonsteroidal anti-inflammatory ' 'drugs, and aspirin in US women. Pharmacoepidemiol Drug Saf. ' '2002;11(8):687–93.', 'journal-title': 'Pharmacoepidemiol Drug Saf'}, { 'key': '363_CR16', 'doi-asserted-by': 'publisher', 'first-page': '7027', 'DOI': '10.1038/srep07027', 'volume': '4', 'author': 'P Yang', 'year': '2014', 'unstructured': 'Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, et al. ' 'Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 ' 'virus-induced acute lung injury. Sci Rep. 2014;4:7027.', 'journal-title': 'Sci Rep'}, { 'issue': '8', 'key': '363_CR17', 'doi-asserted-by': 'publisher', 'first-page': '875', 'DOI': '10.1038/nm1267', 'volume': '11', 'author': 'K Kuba', 'year': '2005', 'unstructured': 'Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of ' 'angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung ' 'injury. Nat Med. 2005;11(8):875–9.', 'journal-title': 'Nat Med'}, { 'issue': '1', 'key': '363_CR18', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1186/s13054-017-1823-x', 'volume': '21', 'author': 'A Khan', 'year': '2017', 'unstructured': 'Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A ' 'pilot clinical trial of recombinant human angiotensin-converting enzyme ' '2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):1–9.', 'journal-title': 'Crit Care'}, { 'key': '363_CR19', 'unstructured': 'Worl Health Organization WH. R&D Blueprint and COVID-19. 2020. ' 'https://www.who.int/teams/blueprint/covid-19. Accessed 12 June 2020.'}, { 'key': '363_CR20', 'doi-asserted-by': 'publisher', 'unstructured': 'Micallef J, Soeiro T, Jonville-Béra AP. French Society of Pharmacology, ' 'Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology ' 'and COVID-19 infection. Therapies. 2020;75(4):355-362. ' 'https://doi.org/10.1016/j.therap.2020.05.003', 'DOI': '10.1016/j.therap.2020.05.003'}, { 'issue': '3', 'key': '363_CR21', 'doi-asserted-by': 'publisher', 'first-page': '364', 'DOI': '10.1007/s11427-020-1643-8', 'volume': '63', 'author': 'Y Liu', 'year': '2020', 'unstructured': 'Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and ' 'biochemical indexes from 2019-nCoV infected patients linked to viral ' 'loads and lung injury. Sci China Life Sci. 2020;63(3):364–74.', 'journal-title': 'Sci China Life Sci'}, { 'key': '363_CR22', 'unstructured': 'ClinicalTrials.gov. LIBERATE Trial in COVID-19 (LIBERATE). 2020. ' 'https://clinicaltrials.gov/ct2/show/NCT04334629. Accessed 12 June 2020.'}, { 'key': '363_CR23', 'doi-asserted-by': 'publisher', 'first-page': '1141', 'DOI': '10.1007/s10787-020-00745-z', 'volume': '28', 'author': 'L Smart', 'year': '2020', 'unstructured': 'Smart L, Fawkes N, Goggin P, et al. A narrative review of the potential ' 'pharmacological influence and safety of ibuprofen on coronavirus disease ' '19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation ' 'and reality. Inflammopharmacol. 2020;28:1141–52. ' 'https://doi.org/10.1007/s10787-020-00745-z.', 'journal-title': 'Inflammopharmacol'}, { 'issue': '8', 'key': '363_CR24', 'first-page': '1021', 'volume': '11', 'author': 'C Amici', 'year': '2006', 'unstructured': 'Amici C, Di Coro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et ' 'al. Indomethacin has a potent antiviral activity against SARS ' 'coronavirus. Antiviral Therapy. 2006;11(8):1021.', 'journal-title': 'Antiviral Therapy'}, { 'issue': '5', 'key': '363_CR25', 'doi-asserted-by': 'publisher', 'first-page': '2231', 'DOI': '10.1128/AAC.02335-12', 'volume': '57', 'author': 'N Lejal', 'year': '2013', 'unstructured': 'Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, et al. ' 'Structure-based discovery of the novel antiviral properties of naproxen ' 'against the nucleoprotein of influenza A virus. Antimicrob Agents ' 'Chemother. 2013;57(5):2231–42.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '6', 'key': '363_CR26', 'doi-asserted-by': 'publisher', 'first-page': '1875', 'DOI': '10.1016/j.celrep.2019.04.053', 'volume': '27', 'author': 'W Zheng', 'year': '2019', 'unstructured': 'Zheng W, Fan W, Zhang S, Jiao P, Shang Y, Cui L, et al. Naproxen ' 'exhibits broad anti-influenza virus activity in mice by impeding viral ' 'nucleoprotein nuclear export. Cell Rep. 2019;27(6):1875-855.e5.', 'journal-title': 'Cell Rep.'}, { 'key': '363_CR27', 'doi-asserted-by': 'crossref', 'unstructured': 'SafiDahaj F. RE: Response to the emerging novel coronavirus outbreak: ' 'British Medical Journal Publishing Group. 2020. ' 'https://www.bmj.com/content/368/bmj.m406/rapid-responses. Accessed 12 ' 'June 2020.', 'DOI': '10.1136/bmj.m406'}, { 'key': '363_CR28', 'unstructured': 'ClinicalTrials.gov. Efficacy of addition of naproxen in the treatment of ' 'critically ill patients hospitalized for COVID-19 infection (ENACOVID). ' '2020. https://clinicaltrials.gov/ct2/show/NCT04325633. Accessed 12 June ' '2020.'}], 'container-title': 'Infectious Diseases and Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://link.springer.com/content/pdf/10.1007/s40121-020-00363-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://link.springer.com/article/10.1007/s40121-020-00363-w/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://link.springer.com/content/pdf/10.1007/s40121-020-00363-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 12]], 'date-time': '2021-03-12T06:39:11Z', 'timestamp': 1615531151000}, 'score': 1, 'resource': {'primary': {'URL': 'http://link.springer.com/10.1007/s40121-020-00363-w'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 11, 2]]}, 'references-count': 28, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2021, 3]]}}, 'alternative-id': ['363'], 'URL': 'http://dx.doi.org/10.1007/s40121-020-00363-w', 'relation': {}, 'ISSN': ['2193-8229', '2193-6382'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Infect Dis Ther', 'published': {'date-parts': [[2020, 11, 2]]}, 'assertion': [ { 'value': '17 September 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 October 2020', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '2 November 2020', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit